Novartis' Entresto flops crucial heart failure trial, imperiling $5B sales goal

Entresto
After a trial flop in treating certain heart failure patients, Novartis' Entresto is unlikely to reach its lofty $5 billion aspirations. (Novartis)

Cardiovascular med Entresto’s blockbuster turn in 2018 was a long time coming for Novartis, which held on to a $5 billion vision for the drug even as its launch lagged. But those dreams took another hit Monday with a major phase 3 trial flop.

Entresto “narrowly missed” its trial goal of reducing deaths and emergency hospitalizations in heart failure patients with preserved ejection fraction (HFpEF) as a combo treatment with valsartan, the company said.

Entresto, which has an FDA approval to treat heart failure patients with reduced ejection fraction (HFrEF), had been poised for a first-ever drug approval in HFpEF. That indication could have brought along a global patient pool of 13 million people, Novartis said.

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

Novartis R&D chief John Tsai said in a release the drugmaker would present the findings from the phase 3 trial, dubbed Paragon-HF, at the European Society of Cardiology Congress in September.

Entresto’s trial flop will take some of the shine off the drug’s recent sales surge after an FDA approval—and slower-than-expected rollout—in 2015. Novartis had hoped a new approval in HFpEF would help the drug power toward top-end sales of $5 billion a year, but now that forecast could be out the window.

RELATED: Novartis expects a parade to blockbusterland, with Entresto leading the way

More importantly, Entresto's shortfall is now the second recent setback for Novartis’ cardiovascular portfolio alongside the FDA’s rejection of canakinumab for patients with prior heart attacks back in October.

In that case, the FDA knocked down the drug’s application after requesting more information on its phase 3 trial responder population. Canakinumab, marketed as Ilaris, posted moderate results in that study with a 15% reduction in cardiovascular risks and 10% cut in cardiovascular deaths—figures one analyst said wouldn’t be "fully compelling to payers."

RELATED: Novartis' canakinumab gets an FDA rejection, but it raises guidance anyway

Taken together, the two failures have set Novartis back in its cardiovascular pursuits, particularly after its arduous journey to ramp up Entresto’s sales to $1.03 billion in 2018.

In late 2017, Novartis pegged slow sales of Entresto to warier-than-expected cardiologists more familiar with traditional cardiovascular meds like warfarin and statins. Once Entresto received positive clinical guidelines from the American College of Cardiology, however, drug sales began to ramp up after repeatedly undershooting analyst and company expectations.

RELATED: The cardiovascular scene to shift by 2024 as next-generation drugs like Eliquis and Xarelto eclipse stalwarts

Those positive results continued in the second quarter after Entresto posted an 81% jump in sales quarter over quarter to hit $421 million. Novartis said booming uptake helped the drug beat analyst consensus by 9% and boost the drugmaker’s total sales of $11.8 billion on the quarter.

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.